- Home
- YSG vs TRML Comparison
YSG vs TRML Comparison
Compare YSG & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YSG
- TRML
- Stock Information
- Founded
- YSG 2016
- TRML 2021
- Country
- YSG China
- TRML United States
- Employees
- YSG N/A
- TRML N/A
- Industry
- YSG Package Goods/Cosmetics
- TRML Biotechnology: Pharmaceutical Preparations
- Sector
- YSG Consumer Discretionary
- TRML Health Care
- Exchange
- YSG Nasdaq
- TRML Nasdaq
- Market Cap
- YSG 396.8M
- TRML 419.1M
- IPO Year
- YSG 2020
- TRML N/A
- Fundamental
- Price
- YSG $3.88
- TRML $27.66
- Analyst Decision
- YSG
- TRML Strong Buy
- Analyst Count
- YSG 0
- TRML 3
- Target Price
- YSG N/A
- TRML $64.67
- AVG Volume (30 Days)
- YSG 275.6K
- TRML 202.3K
- Earning Date
- YSG 11-19-2024
- TRML 11-07-2024
- Dividend Yield
- YSG N/A
- TRML N/A
- EPS Growth
- YSG N/A
- TRML N/A
- EPS
- YSG N/A
- TRML N/A
- Revenue
- YSG $462,190,479.00
- TRML N/A
- Revenue This Year
- YSG $2.29
- TRML N/A
- Revenue Next Year
- YSG $5.70
- TRML N/A
- P/E Ratio
- YSG N/A
- TRML N/A
- Revenue Growth
- YSG N/A
- TRML N/A
- 52 Week Low
- YSG $1.99
- TRML $12.12
- 52 Week High
- YSG $4.89
- TRML $48.31
- Technical
- Relative Strength Index (RSI)
- YSG 60.56
- TRML 58.78
- Support Level
- YSG $3.77
- TRML $25.10
- Resistance Level
- YSG $4.00
- TRML $28.35
- Average True Range (ATR)
- YSG 0.16
- TRML 1.37
- MACD
- YSG 0.02
- TRML -0.26
- Stochastic Oscillator
- YSG 79.66
- TRML 57.98
About YSG Yatsen Holding Limited
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The Group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.